Author

E. U. Igumbor

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. A. Adamu· 2 shared A. Y. Bello· 2 shared A. Yunusa· 2 shared C. L. Ochu· 2 shared I. Okoye· 2 shared M. A. Popoola· 2 shared M. B. Bello· 2 shared M. U. Imam· 2 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

A. A. Adamu

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Erythromycin, Retapamulin, Pyridoxine, Folic acid, and Ivermectin dose-dependently inhibit cytopathic effect, Papain-like Protease, and MPRO of SARS-CoV-2

S. O. Bello, M. U. Imam, M. B. Bello, A. Yunusa, A. A. Adamu, A. Shuaibu, E. U. Igumbor, Z. G. Habib, M. A. Popoola, C. L. Ochu, A. Y. Bello, Y. Y. Deeni, I. Okoye

The paper shows that Erythromycin, Retapamulin, Pyridoxine, Folic acid, and Ivermectin inhibit SARS-CoV-2 cytopathic effect and proteases in a dose-dependent manner, with IC50 values within clinical concentrations for most drugs.

bioRxiv · Dec 28, 2022 · PreprintPharmacology & Toxicology

Innovative, rapid, high throughput method for drug repurposing in a pandemic - a case study of SARS-CoV-2 and COVID-19

S. O. Bello, A. Yunusa, A. A. Adamu, M. U. Imam, M. B. Bello, A. B. Shuaibu, E. U. Igumbor, Z. G. Habib, M. A. Popoola, C. L. Ochu, A. Y. Bello, Y. Y. Deeni, I. Okoye

This study identifies potential drugs for COVID-19 by combining computational and wet-lab methods, finding that erythromycin, pyridoxine, folic acid, and retapamulin inhibit SARS-CoV-2 induced cytopathic effect in Vero cells at clinically achievable concentrations.

bioRxiv · Dec 25, 2022Pharmacology & Toxicology